Fig. 2From: Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia studyReduction of time in the hospital as a result of conversion of (a) trastuzumab and (b) rituximab from IV to SC administration, and as a result of hypothetical maximum conversion of (c) trastuzumab and (d) rituximab from IV to SC administration. IV intravenous, SC subcutaneousBack to article page